Immutep (ASX:IMM) Days Sales Outstanding : 0.00 (As of Dec. 2023)

View and export this data going back to 1988. Start your Free Trial

What is Immutep Days Sales Outstanding?

Immutep's average Accounts Receivable for the three months ended in Dec. 2023 was A$0.16 Mil. Immutep's Revenue for the three months ended in Dec. 2023 was A$0.00 Mil.

The historical rank and industry rank for Immutep's Days Sales Outstanding or its related term are showing as below:

During the past 13 years, Immutep's highest Days Sales Outstanding was 10672.34. The lowest was 73.00. And the median was 286.37.

ASX:IMM's Days Sales Outstanding is not ranked ^*
in the Biotechnology industry.
Industry Median: 72.19
* Ranked among companies with meaningful Days Sales Outstanding only.

Immutep's Days Sales Outstanding stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Immutep Days Sales Outstanding Historical Data

The historical data trend for Immutep's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immutep Days Sales Outstanding Chart

Immutep Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Days Sales Outstanding

Get a 7-Day Free Trial

10,672.34

120.16

73.00

Immutep Quarterly Data
	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison of Immutep's Days Sales Outstanding

For the Biotechnology subindustry, Immutep's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immutep's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immutep's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Immutep's Days Sales Outstanding falls into.

Immutep Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Immutep's Days Sales Outstanding for the fiscal year that ended in Jun. 2023 is calculated as

	Days Sales Outstanding (A: Jun. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Jun. 2022 )	+	Accounts Receivable (A: Jun. 2023 ))	/	count )	/	Revenue (A: Jun. 2023 )	*	Days in Period
=	( (0.017	+	0.131)	/	2 )	/	0	*	365
=	0.074					/	0	*	365
=	N/A

Immutep's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (0	+	0.161)	/	1 )	/	0	*	365 / 4
=	0.161					/	0	*	365 / 4
=	N/A

Immutep (ASX:IMM) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Immutep Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Immutep's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Immutep (ASX:IMM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immutep Ltd (ASX:IMM) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

PRRUF:USA IMMP:USA YP1B:Germany

Address

264 George Street, Level 33, Australia Square, Sydney, NSW, AUS, 2000

Website

https://www.immutep.com

Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trails, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia and derives the majority of the revenue from the sale of the products.

Immutep (ASX:IMM) Headlines

No Headlines